 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value of EGFR Inhibitors
November 28, 2012
Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value of EGFR Inhibitors
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter - BMS, Amgen's Trials in Wild-Type KRAS Patients Could Clarify PGx Labeling for CRC Drugs
December 7, 2011 / Pharmacogenomics Reporter - Competing Pharmas Race to Pinpoint Markers Beyond KRAS for Personalized Colorectal Cancer Rx
April 21, 2010 / Pharmacogenomics Reporter - Palmetto's Initial MDx Pricing Disappoints Industry; Raises Concerns about Business Impact
February 6, 2013 / Pharmacogenomics Reporter - Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter